Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab-based regimen versus conventional therapy for remission induction in EGPA
2020-003318-10Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mepolizumab, cyclophosphamide and azathioprine in eosinophilic granulomatosis with polyangiitis (EGPA) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Started Jun 2021; status: active.
02
Drugs
mepolizumabcyclophosphamideazathioprine
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on 2020-003318-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003318-10.